Pacira BioSciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Pacira BioSciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

2.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	2.8%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Recent updates

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Sep 06

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Jul 23

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Jun 07

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PCRX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PCRX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Pacira BioSciences Piyasaya Karşı Temettü Getirisi

PCRX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PCRX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (PCRX) (3 yıla kadar)	n/a

Önemli Temettü: PCRX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PCRX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PCRX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PCRX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Pacira BioSciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Recent updates

Pacira BioSciences, Inc. Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Pacira BioSciences, Inc. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2024

Pacira BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Pacira BioSciences, Inc. Announces Chief Financial Officer Changes

Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

DOMA Perpetual Capital Management Sends Letter to the Board of Directors of Pacira Biosciences

Investor sentiment improves as stock rises 15%

Pacira Biosciences, Inc. Announces Board Changes

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Investor sentiment deteriorates as stock falls 44%

CEO & Director recently bought US$100k worth of stock

Price target decreased by 46% to US$20.83

New major risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Pacira BioSciences, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Investor sentiment deteriorates as stock falls 20%

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Investor sentiment improves as stock rises 16%

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Pacira BioSciences records 17.7% sequential growth in August revenue

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences provides update on July product sales